ESAIC News Highlights


The Lancet: Preliminary results from Russian trials find that vaccine candidates led to no serious adverse events and elicit antibody response

The new paper reports the findings of two open-label, non-randomised phase 1/2 trials looking at a frozen formulation and a freeze-dried formulation of a two-part vaccine. The two-part vaccine included two adenovirus vectors – recombinant human adenovirus type 26 (rAd26-S) and recombinant human adenovirus type 5 (rAd5-S)
In the phase 1 part of each trial, the individual components of the two-part vaccine (rAd26-S and rAd5-S) were tested for safety. The phase 2 study then tested whether…

Latest news

Apply now for bursaries to Euroanaesthesia 2020

We at the ESAIC have teamed up with the WFSA (World Federation of Societies of Anaesthesiologists) to offer bursaries to Euroanaesthesia 2020. This year Euroanaesthesia will be a virtual congress enti...

Welcome to the new EJA Editor-in-Chief

The ESAIC is very happy to welcome aboard our newest Editor-in-Chief (EIC) for the European Journal of Anaesthesiology (EJA), Charles Marc Samama. His role officially started on 14 September 2020. Ch...